Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?

Journal of Medicinal Chemistry

Volumn 47, Issue 11, 2004, Pages 2717-2723

  Szallasi, Arpad ^a   Appendino, Giovanni ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CAPSAZEPINE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR TRPV1; VANILLOID RECEPTOR TRPV1 ANTAGONIST;

ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HYPERTENSION; INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; RAT; RISK BENEFIT ANALYSIS; SHORT SURVEY; SIDE EFFECT; STOMACH ULCER; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; CAPSAICIN; DRUG DESIGN; HUMANS; RECEPTORS, DRUG;

EID: 2442642767     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030560j     Document Type: Short Survey

References (52)

1. Szallasi, A.; Blumberg, P. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev. 1999, 51, 159-211.
2. Montell, C.; Birnbaumer, L.; Flokerzi, V.; Bindels, R. J.; Brufors, E. A.; Caterina, M. J.; Clapman, D. E.; Harteneck, C.; Heller, C.; Julius, D. E. A unified nomenclature for the superfamily of TRP cation channels. Mol. Cell 2002, 9, 229-231.
3. Di Marzo, V.; Blumberg, P. M.; Szallasi, A. Endovanilloid signalling in pain. Curr. Opin. Neurobiol. 2002, 12, 372-379.
4. Sterner, O.; Szallasi, A. Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. Trends Pharmacol. Sci. 1999, 20, 431-439.
5. Gunthorpe, M. J.; Benham, C. D.; Randall, A.; Davis, J. B. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci. 2002, 23, 183-191.
6. Birnbaumer, L.; Yidirim, E.; Abramowitz, J. A comparison of the genes coding for canonical TRP channels and their M, V, and P relatives. Cell Calcium 2003, 33, 419-432.
7. Caterina, M. J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001, 24, 487-517.
8. Prescott, E. D.; Julius, D. A modular PIP2 binding site as the determinant of capsaicin receptor sensitivity. Science 2003, 300, 1284-1288.
9. Chu, C. J.; Huang, S. M.; De Petrocellis, L.; Bisogno, T.; Ewing, S. A.; Miller, J. D.; Zipkin, R. E.; Daddario, N.; Appendino, G.; Di Marzo, V.; Walker, J. M. N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem. 2003, 278, 13633-13639.
10. Jordt, S. E.; Julius, D. Molecular basis for species-specific sensitivity to "hot" chilli peppers. Cell 2002, 108, 421-430.
11. Amann, R.; Maggi, C. A. Ruthenium red as a capsaicin antagonist. Life Sci. 1991, 49, 849-856.
12. Walpole, C. S.; Bevan, S.; Bovermann, G.; Boelsterli, J. J.; Breckenridge, R.; Davies, J. W.; Hughes, G. A.; Oberer, L.; Winter, J. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem. 1994, 24, 1942-1954.
13. Santos, A. R.; Calixto, J. B. Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice. Life Sci. 1997, 235, 73-76.
14. Kwak, J. Y.; Jung, J. Y.; Hwang, S. W.; Lee, W. T.; Oh, U. A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced responses in the rat: evidence for an endogenous capsaicin-like substance. Neuroscience 1998, 86, 619-626.
15. Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 2003, 304, 56-62.
16. Wahl, P.; Toged, C.; Soren, T.; Thomsen, C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol. Pharmacol. 2001, 59, 9-15.
17. McDonnel, M. E.; Zhang, S.-P.; Dubin, A. E.; Dax, S. L. Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor. Bioorg. Med. Chem. Lett. 2002, 12, 1189-1192.
18. Appendino, G.; Harrison, S.; De Petrocellis, L.; Daddario, N.; Bianchi, F.; Schiano-Moriello, A.; Trevisa, M.; Benvenuti, F.; Geppetti, P.; Di Marzo, V. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br. J. Pharmacol. 2003, 139, 1417-1424.
19. Seabrook, G. R.; Sutton, K. G.; Jarolimek, W.; Hollingworth, G. J.; Teague, S.; Webb, J.; Clark, N.; Boyce, S.; Kerby, J.; Ali, Z.; Chou, M.; Middleton, R.; Kaczorowski, G.; Jones, A. B. Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo resiniferatoxin. J. Pharmacol. Exp. Ther. 2002, 303, 1052-1060.
20. Bakthavatchalam, R. Capsaicin receptor ligands. WO 0208221-A, 2002.
21. Tóth, A.; Blumberg, P. M.; Chen, Z.; Kozikowski, A. P. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. Mol. Pharmacol. 2004, 65, 282-291.
22. Lee, J.; Lee, J.; Kang, M., Shin, M.; Kim, J.-M.; Kang, S.-U.; Lim, J.-O.; Choi, H.-K.; Suh, Y.-G.; Park, H.-G.; Oh, U.; Kim, H.-D.; Park, Y.-H.; Ha, H.-J.; Kim, Y.-H.; Toth, A.; Wang, Y.; Tran, R.; Pearce, L. V.; Lundberg, D. J.; Blumberg, P. M. N-(3-Acyloxy-2-benzylpropyl)-N′ -[4-(methylsulfonylamino)benzyl]thiourea analogues: Novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor. J. Med. Chem. 2003, 46, 3116-3126.
23. Wang, Y.; Szabó, T.; Welter, J. D.; Tóth, A.; Tran, R.; Lee, J. Y.; Kang, S. U.; Suh, Y. G.; Blumberg, P. M.; Lee, J. High affinity antagonists of the vanilloid receptor. Mol. Pharmacol. 2002, 62, 947-956.
24. Wrigglesworth, R.; Walpole, C. S.; Bevan, S. J.; Campbell, E. A.; Dray, A.; Hughes, G. A.; James, I. F.; Masdin, K. J.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents: Structure-activity studies. Part 4. Potent orally-active analgesics. J. Med. Chem. 1996, 39, 4941-4951.
25. Rami, H. K.; Davis, J. B.; Gunthorpe, M. J.; Jerman, J. C.; Gray, J.; Smith, G. D.; Randall, A. D.; Davies, C. H.; Gill, C. H.; Thompson, M.; Smart, D.; Wyman, P. Identification of SB-366791, a potent and selective antagonist of vanilloid receptor-1. Drugs Future 2002, 27 (Suppl. A), 411.
26. Yoon, J. W.; Choi, H. Y.; Lee, H. J.; Ryu, C. H.; Park, H.; Suh, Y.; Oh, U.; Jeong, Y. S.; Choi, J. K.; Park, Y.-H.; Kim, H.-D. Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1549-1552.
27. Tóth, A.; Kedei, N.; Szabó, T.; Wang, Y.; Blumberg, P. M. Thapsigargin binds to and inhibits the cloned vanilloid receptor-1. Biochem. Biophys. Res. Commun. 2002, 293, 777-782.
28. Lee, S. H.; Premkumar, L. S. Inhibition of capsaicin-induced single channel currents by cocaine. Soc. Neurosci. Abstr. 1999, 25, P2255.
29. Hahn, J. H. Ginsenosides inhibit capsaicin channels in rat dorsal root ganglion neurons. Neurosci. Lett. 2000, 287, 45-48.
30. Thompson, M.; Wyman, P. A. Urea derivatives having vanilloid receptor (VR1) antagonist activity. WO 02072536-A, 2002.
31. Rami, H. K.; Thompson, M.; Wyman, P. A. Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists. WO 02090326-A, 2002.
32. Rami, H. K.; Thompson, M.; Wyman, P. A. Novel compounds. WO 03022809-A, 2003.
33. Yura, T.; Mogi, M.; Ikegami, Y.; Masuda, T.; Kokubo, T.; Urbahns, K.; Lowinger, T. B.; Yoshida, N.; Freitag, J. Amine derivatives. WO 03014064-A, 2003.
34. Culshaw, A. J.; Gull, P.; Hallett, A.; Kim, H.-Y; Seiler, M. P.; Zimmermann, K.; Liu, Y.; Prashad, M. Pyridine derivatives. WO 0276946-A.
35. Dax, S.; Dubin, A.; Jetter, M.; Nasser, N.; Shah, C.; Swanson, D.; Carruthers, N. I. Vanilloid receptor antagonists: structure-activity relationships via parallel and targeted synthesis. Drugs Future 2002, 27 (Suppl. A), 93.
36. Sun, Q.; Tafesse, L.; Islam, K.; Zhou, X.; Victory, S. F.; Zhang, C.; Hachicha, M.; Schmid, L. A.; Patel, A.; Rotshteyn, Y.; Valenzano, K. J.; Kyle, D. J. 4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 3611-3616.
37. García-Martínez, C.; Humet, M.; Planells-Cases, R.; Gomis, A.; Caprini, M.; Viana, F.; De la Peña, E.; Sanchez-Baeza, F.; Carbonell, T.; De Felipe, C.; Pérez-Payá, E.; Belmonte, C.; Messeguer, A.; Ferrer-Montiel, A. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2374-2379.
38. Grunweller, A.; Wyszko, E.; Bieber, B.; Jahnel, R.; Erdmann, V. A.; Kurreck, J. Comparison of different antisense strategies in ammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acid Res. 2003, 31, 3185-3193.
39. Kamei, J.; Zushida, K.; Morita, K.; Sasaki, M.; Tanaka, S. Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur. J. Pharmacol. 2001, 422, 83-86.
40. Ji, R.-R.; Samad, T. A.; Jin, S.-X.; Schmoll, R.; Woolf, C. J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36, 57-68.
41. Rashid, M. H.; Inoue, M.; Bakoshi, S.; Ueda, H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J. Pharmacol. Exp. Ther. 2003, 306, 709-717.
42. Yiangou, Y.; Facer, P.; Dyer, N. H. C.; Chan, C. L. H.; Knowles, C.; Williams, N. S.; Anand, P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001, 357, 1338-1339.
43. Chan, C. L.; Facer, P.; Davis, J. B.; Smith, G. D.; Egerton, J.; Bountra, C.; Williams, N. S.; Anand, P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003, 361, 385-391.
44. Ahluwalia, J.; Urban, L.; Bevan, S.; Nagy, I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci. 2003, 17, 2611-2618.
45. Kihara, N.; de la Fuente, S. G.; Fujino, K.; Takahashi, T.; Pappas, T. N.; Mantyh, C. R. Vanilloid receptor-1 containing primary sensory neurons mediate dextran sulphate sodium-induced colitis in rats. Gut 2003, 52, 713-719.
46. McVey, D. C.; Schmid, P. C.; Schmid, H. H.; Vigna, S. R. Endocannabinoids induce ileitis in rats via the capsaicin receptor VR1. J. Pharmacol. Exp. Ther. 2003, 304, 713-722.
47. Szallasi, A. Vanilloid (capsaicin) receptors in health and disease. Am. J. Clin. Pathol. 2002, 118, 110-121.
48. Veldhuis, W. B.; van der Stelt, M.; Wadman, M. W.; van Zadelhoff, G.; Maccarrone, M.; Fezza, F.; Veldin, G. A.; Vliegenthart, J. F.; Bar, P. R.; Nicolay, K.; Di Marzo, V. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vitro excitotoxiciy in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 2003, 23, 4127-4133.
49. Lastres-Becker, I.; de Miguel, R.; De Petrocellis, L.; Makriyannis, A.; Di Marzo, V.; Fernandez-Ruiz, J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 2003, 84, 1097-1109.
50. Marinelli, S.; Di Marzo, V.; Berretta, N.; Matias, I.; Maccarrone, M.; Bernardi, G.; Mercuri, N. B. Presynaptic facilitation of glutaminergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 2003, 23, 3136-3144.
51. Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Effects of vanilloid receptor agonists and antagonists on gastric antral ulcers in rats. Eur. J. Pharmacol. 2001, 432, 203-210.
52. Li, J.; Kaminski, N. E.; Wang, D. H. Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 2003, 41, 757-762.